High-Dose Flu Vaccine Linked to Lower Alzheimer's Risk in Study
A study published in Neurology suggests high-dose flu vaccines for adults over 65 are linked to fewer Alzheimer's diagnoses compared to standard doses, though further research is needed.
A recent study led by UTHealth Houston and published in the journal Neurology indicates that high-dose influenza vaccines for adults aged 65 and older are associated with fewer new diagnoses of Alzheimer's disease compared to standard-dose vaccines.
Researchers analyzed health insurance data from the USA, tracking 120,775 participants in the high-dose group and 44,022 in the standard-dose group over a period of up to three years. None of the participants showed evidence of cognitive impairment at the start of the observation.
During the first 25 months, the cumulative risk of an Alzheimer's diagnosis was lower among those who received the high-dose vaccine, with an absolute difference estimated at about 0.54 percentage points—roughly five fewer cases per thousand vaccine recipients.
Understanding the High-Dose Vaccine
As people age, immune system activity declines. High-dose flu vaccines contain four times the amount of antigen compared to standard inactivated vaccines, aiming to trigger a stronger immune response and improve protection against influenza.
While the study shows a promising observational advantage, researchers emphasize that it was an observational study based on administrative claims rather than a randomized clinical trial. Consequently, it cannot prove direct causation, and further prospective research is required to determine potential mechanisms and clinical recommendations.
Current Medical Recommendations
Public health agencies, including the USA Centers for Disease Control and Prevention, generally recommend high-dose, recombinant, or adjuvanted influenza vaccines for adults aged 65 and older to prevent severe respiratory illness and complications.
Local health authorities continue to advise annual influenza vaccination for older adults, noting that while potential secondary cognitive benefits are intriguing, protection against seasonal flu remains a well-established priority.
